Dashboard
Discussions
Watchlists
Collections
More
Events
Tools
SIGN UP
SIGN IN
ENTITY
Sihuan Pharmaceutical Hldgs (460 HK)
Watchlist
42
Analysis
Health Care
•
China
Sihuan Pharmaceutical Holdings Group Ltd. researches and develops cardiocerebral vascular drugs in China. The Company drugs address needs in the areas of anti-infective, metabolism, cardiovascular system, oncology and nervous system.
more
Watchlist
All
Insights
Broker Reports
Sponsored
Refresh
Focused
Relevant
bearish
•
The United Laboratories International Holdings Limited
•
19 Sep 2023 12:21
United Laboratories International Holdings Placement (3933.HK) - Valuation Pullback Seems Inevitable
United Lab is facing a performance decline when the dividend period of the pandemic has subsided. Weight management/veterinary drug businesses have...
Xinyao (Criss) Wang
403 Views
Share
bearish
•
Shanghai Haohai Biological Technology
•
10 Feb 2023 08:55
Shanghai Haohai Biological Technology (688366.CH/6826.HK)- Disappointing Earnings and Gloomy Outlook
Continuous M&A fails to bring ideal performance to Haohai. Medical aesthetics is the main growth driver, but Haohai is lack of competitiveness....
Xinyao (Criss) Wang
267 Views
Share
bearish
•
Sihuan Pharmaceutical Hldgs
•
29 Nov 2022 08:45
Sihuan Pharmaceutical (460.HK) - About the Recent Business Adjustments and the Outlook
Sihuan's pursuing strategic adjustments actively, but its business transformation may not end up well without persuasive long logic. We recommend...
Xinyao (Criss) Wang
267 Views
Share
bullish
•
Bloomage Biotechnology Lt
•
17 Oct 2022 08:50
Bloomage Biotechnology (688363.CH) - Positioning and Strategic Layout Imply Strong Upside Potential
Synthetic biology/industrial chain integration help Bloomage build high moat.Synergy of multiple business improve the resilience to market...
Xinyao (Criss) Wang
163 Views
Share
bullish
•
Sihuan Pharmaceutical Hldgs
•
27 Jul 2022 09:03
Sihuan Pharmaceutical (460.HK) - The Potential Disposal of Generic Drug Business and the Outlook
The medical aesthetics/innovative drug business face various challenges.Though Sihuan is undervalued,concerns on outlook/development mode will...
Xinyao (Criss) Wang
250 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.23.1
x